Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma.
Biomarkers, Tumor
Biopsy
Computational Biology
/ methods
DNA Mutational Analysis
/ methods
Disease Management
Disease Susceptibility
Gene Expression Profiling
Genetic Heterogeneity
High-Throughput Nucleotide Sequencing
Humans
Mesothelioma, Malignant
/ diagnosis
Molecular Diagnostic Techniques
Molecular Sequence Annotation
Mutation
Pleural Neoplasms
/ diagnosis
Precision Medicine
/ methods
Prognosis
Tumor Microenvironment
/ genetics
Exome Sequencing
Clonality
NF2 subclonal mutation
Spatial molecular intra-tumor heterogeneity
Thoracic tumor
Tumor microenvironment
Journal
Genome medicine
ISSN: 1756-994X
Titre abrégé: Genome Med
Pays: England
ID NLM: 101475844
Informations de publication
Date de publication:
14 07 2021
14 07 2021
Historique:
received:
09
11
2020
accepted:
30
06
2021
entrez:
15
7
2021
pubmed:
16
7
2021
medline:
17
2
2022
Statut:
epublish
Résumé
Malignant pleural mesothelioma (MPM) is a heterogeneous cancer. Better knowledge of molecular and cellular intra-tumor heterogeneity throughout the thoracic cavity is required to develop efficient therapies. This study focuses on molecular intra-tumor heterogeneity using the largest series to date in MPM and is the first to report on the multi-omics profiling of a substantial series of multi-site tumor samples. Intra-tumor heterogeneity was investigated in 16 patients from whom biopsies were taken at distinct anatomical sites. The paired biopsies collected from apex, side wall, costo-diaphragmatic, or highest metabolic sites as well as 5 derived cell lines were screened using targeted sequencing. Whole exome sequencing, RNA sequencing, and DNA methylation were performed on a subset of the cohort for deep characterization. Molecular classification, recently defined histo-molecular gradients, and cell populations of the tumor microenvironment were assessed. Sequencing analysis identified heterogeneous variants notably in NF2, a key tumor suppressor gene of mesothelial carcinogenesis. Subclonal tumor populations were shared among paired biopsies, suggesting a polyclonal dissemination of the tumor. Transcriptome analysis highlighted dysregulation of cell adhesion and extracellular matrix pathways, linked to changes in histo-molecular gradient proportions between anatomic sites. Methylome analysis revealed the contribution of epigenetic mechanisms in two patients. Finally, significant changes in the expression of immune mediators and genes related to immunological synapse, as well as differential infiltration of immune populations in the tumor environment, were observed and led to a switch from a hot to a cold immune profile in three patients. This comprehensive analysis reveals patient-dependent spatial intra-tumor heterogeneity at the genetic, transcriptomic, and epigenetic levels and in the immune landscape of the tumor microenvironment. Results support the need for multi-sampling for the implementation of molecular-based precision medicine.
Sections du résumé
BACKGROUND
Malignant pleural mesothelioma (MPM) is a heterogeneous cancer. Better knowledge of molecular and cellular intra-tumor heterogeneity throughout the thoracic cavity is required to develop efficient therapies. This study focuses on molecular intra-tumor heterogeneity using the largest series to date in MPM and is the first to report on the multi-omics profiling of a substantial series of multi-site tumor samples.
METHODS
Intra-tumor heterogeneity was investigated in 16 patients from whom biopsies were taken at distinct anatomical sites. The paired biopsies collected from apex, side wall, costo-diaphragmatic, or highest metabolic sites as well as 5 derived cell lines were screened using targeted sequencing. Whole exome sequencing, RNA sequencing, and DNA methylation were performed on a subset of the cohort for deep characterization. Molecular classification, recently defined histo-molecular gradients, and cell populations of the tumor microenvironment were assessed.
RESULTS
Sequencing analysis identified heterogeneous variants notably in NF2, a key tumor suppressor gene of mesothelial carcinogenesis. Subclonal tumor populations were shared among paired biopsies, suggesting a polyclonal dissemination of the tumor. Transcriptome analysis highlighted dysregulation of cell adhesion and extracellular matrix pathways, linked to changes in histo-molecular gradient proportions between anatomic sites. Methylome analysis revealed the contribution of epigenetic mechanisms in two patients. Finally, significant changes in the expression of immune mediators and genes related to immunological synapse, as well as differential infiltration of immune populations in the tumor environment, were observed and led to a switch from a hot to a cold immune profile in three patients.
CONCLUSIONS
This comprehensive analysis reveals patient-dependent spatial intra-tumor heterogeneity at the genetic, transcriptomic, and epigenetic levels and in the immune landscape of the tumor microenvironment. Results support the need for multi-sampling for the implementation of molecular-based precision medicine.
Identifiants
pubmed: 34261524
doi: 10.1186/s13073-021-00931-w
pii: 10.1186/s13073-021-00931-w
pmc: PMC8281651
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
113Informations de copyright
© 2021. The Author(s).
Références
Lancet. 2016 Apr 2;387(10026):1405-1414
pubmed: 26719230
Nucleic Acids Res. 2019 Jul 2;47(W1):W199-W205
pubmed: 31114916
Genome Biol. 2014;15(12):550
pubmed: 25516281
Nat Commun. 2019 Mar 22;10(1):1333
pubmed: 30902996
Biomark Res. 2020 Aug 26;8:34
pubmed: 32864131
Carcinogenesis. 2019 Jul 6;40(6):724-734
pubmed: 31038674
Int J Mol Sci. 2020 Apr 10;21(7):
pubmed: 32290245
Int J Mol Sci. 2018 May 30;19(6):
pubmed: 29848954
Int J Mol Sci. 2018 Mar 26;19(4):
pubmed: 29587439
Bioinformatics. 2015 Jan 15;31(2):166-9
pubmed: 25260700
Cancer Cell. 2020 Jan 13;37(1):8-19
pubmed: 31935374
Nucleic Acids Res. 2016 Sep 19;44(16):e131
pubmed: 27270079
Int J Mol Sci. 2018 Jul 27;19(8):
pubmed: 30060470
Lancet. 2021 Jan 30;397(10272):375-386
pubmed: 33485464
Bioinformatics. 2018 Oct 1;34(19):3380-3381
pubmed: 29771315
Nat Commun. 2017 Nov 3;8(1):1315
pubmed: 29101368
Clin Cancer Res. 2017 Jun 15;23(12):3191-3202
pubmed: 28003305
Arch Pathol Lab Med. 2018 Jan;142(1):89-108
pubmed: 28686500
Front Oncol. 2020 Feb 21;10:187
pubmed: 32154179
Nat Rev Cancer. 2018 Nov;18(11):696-705
pubmed: 30293088
Cytopathology. 2015 Jun;26(3):142-56
pubmed: 26052757
Arch Pathol Lab Med. 2013 May;137(5):647-67
pubmed: 22929121
Nat Rev Drug Discov. 2020 Jul;19(7):480-494
pubmed: 32555376
Nat Biotechnol. 2013 Mar;31(3):213-9
pubmed: 23396013
Eur J Surg Oncol. 2020 Apr;46(4 Pt A):656-666
pubmed: 31706719
J Thorac Oncol. 2020 Jun;15(6):1037-1053
pubmed: 32165206
EBioMedicine. 2019 Oct;48:191-202
pubmed: 31648983
Int J Mol Sci. 2018 Mar 30;19(4):
pubmed: 29601534
Cancer. 2019 Dec 1;125(23):4164-4171
pubmed: 31390057
Cancer Cytopathol. 2013 Aug;121(8):415-22
pubmed: 23450849
Nat Genet. 2016 Apr;48(4):407-16
pubmed: 26928227
J Thorac Oncol. 2019 Feb;14(2):276-287
pubmed: 30316012
Front Immunol. 2019 Dec 20;10:2854
pubmed: 31921125
Genes Dev. 1998 Apr 15;12(8):1121-33
pubmed: 9553042
Front Genet. 2019 May 03;10:421
pubmed: 31130993
Lancet Oncol. 2019 Feb;20(2):239-253
pubmed: 30660609
Ann Pathol. 2014 Feb;34(1):51-63
pubmed: 24630637
Clin Cancer Res. 2014 Mar 1;20(5):1323-34
pubmed: 24443521
Genome Biol. 2016 Oct 20;17(1):218
pubmed: 27765066
Histopathology. 2020 Jul;77(1):55-66
pubmed: 32170970
Mol Oncol. 2020 Jun;14(6):1207-1223
pubmed: 32083805
J Thorac Oncol. 2020 Jan;15(1):29-49
pubmed: 31546041
Clin Cancer Res. 2020 Oct 15;26(20):5477-5486
pubmed: 32816946
Proc Natl Acad Sci U S A. 2016 Nov 22;113(47):13432-13437
pubmed: 27834213
Oncogene. 2001 Jul 12;20(31):4249-57
pubmed: 11464291
Nucleic Acids Res. 2019 Jan 8;47(D1):D853-D858
pubmed: 30407534
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Anticancer Res. 2014 Apr;34(4):1595-600
pubmed: 24692687
Nat Commun. 2018 Dec 7;9(1):5235
pubmed: 30531861
Cancer Discov. 2018 Dec;8(12):1548-1565
pubmed: 30322867
Oncoimmunology. 2017 Jan 6;6(2):e1278330
pubmed: 28344893
Genome Biol. 2013 Apr 25;14(4):R36
pubmed: 23618408
Front Oncol. 2020 Mar 25;10:388
pubmed: 32269966
J Transl Med. 2014 Dec 04;12:301
pubmed: 25471750
J Thorac Cardiovasc Surg. 2020 Oct;160(4):1078-1083.e2
pubmed: 32475501
Bioinformatics. 2007 Mar 15;23(6):657-63
pubmed: 17234643
Bioinformatics. 2015 Jun 15;31(12):2032-4
pubmed: 25697820
Int J Mol Sci. 2020 Jun 17;21(12):
pubmed: 32560575